News
Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback